Myeloperoxidase, a risk indicator for cardiovascular disease
AssigneeThe Cleveland Clinic Foundation
InventorsStanley L. Hazen, Renliang Zhang
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Cleveland Clinic Foundation
InventorsStanley L. Hazen, Renliang Zhang
Estimating the term…
Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from the general population or a select population of human subjects. Such comparison characterizes the test subject's risk of developing CVD.
1-22. (canceled)
A method for administering a lipid lowering agent to a human patient based on elevated levels of myeloperoxidase (MPO) comprising:
The method of claim 1, wherein said bodily sample is plasma.
The method of claim 1, wherein bodily sample is serum.
The method of claim 1, further comprising:
Dependencies are inferred from the claim text.